| PRECLINICAL | evidence | Real-World Effectiveness of Tirzepatide in Japanese Patients with Type 2 Diabetes: A Multicenter Retrospective Observational Study. | Tirzepatide | — | 2026-07-01 |
| PRECLINICAL | evidence | Comparative Efficacy and Safety of Tirzepatide in Asian and Non-Asian Adults With Obesity Without Diabetes: A Systematic Review and Meta-Analysis. | Tirzepatide | Weight & fat loss | 2026-07-01 |
| PRECLINICAL | evidence | Patients' Experiences of Obstructive Sleep Apnea and Tirzepatide Treatment: An Exit Interview Study. | Tirzepatide | Sleep quality · n = 82 | 2026-07-01 |
| PRECLINICAL | evidence | Tirzepatide-Associated Lithium Toxicity Necessitating Hemodialysis in Previously Stable Bipolar I Disorder. | Tirzepatide | — | 2026-07-01 |
| PRECLINICAL | evidence | Tirzepatide in Metabolic Diseases: Clinical Efficacy and Safety Beyond Diabetes and Obesity. | Tirzepatide | — | 2026-07-01 |
| PRECLINICAL | evidence | Effects of Tirzepatide on Metabolic Parameters in Patients with Psoriasis and Obesity: 24-Week Real-World Study. | Tirzepatide | — | 2026-07-01 |
| PRECLINICAL | evidence | Tirzepatide for weight and behavior management in a patient with Smith-Magenis syndrome. | Tirzepatide | — | 2026-07-01 |
| PRECLINICAL | evidence | Hypersensitivity Reaction to Tirzepatide With Demonstrated Tolerance to Semaglutide: A Case Report. | Tirzepatide | — | 2026-07-01 |
| PRECLINICAL | evidence | Hair Loss in Patients on Glucagon-Like Peptide 1 Receptor Agonists: Understanding Risks and Managing Outcomes. | Tirzepatide | — | 2026-07-01 |
| PRECLINICAL | evidence | Real-World vs. Randomized Trial Evidence for Incretin-Based Therapies: A Narrative Review. | Tirzepatide | — | 2026-07-01 |
| PRECLINICAL | evidence | Tolerability and Effectiveness of Tirzepatide in Kidney Transplant Recipients: Real-world Experience From a Single-center Study. | Tirzepatide | — | 2026-07-01 |
| PRECLINICAL | evidence | Cardiovascular and Cerebrovascular Outcomes Risk Reduction Associated With Semaglutide vs Tirzepatide: A Target Trial Emulation. | Tirzepatide | — | 2026-07-01 |
| PRECLINICAL | evidence | Dose-Response and Clinical Equivalence of Semaglutide and Tirzepatide for Weight Loss in Type 2 Diabetes: A Model-Based Analysis. | Tirzepatide | — | 2026-07-01 |
| PRECLINICAL | evidence | Comparative effectiveness of tirzepatide and DPP-4 inhibitors in type 2 diabetes with heart failure. | Tirzepatide | — | 2026-07-01 |
| PRECLINICAL | evidence | Dulaglutide in the era of tirzepatide and semaglutide: reaffirming its role in contemporary cardiometabolic care. | Tirzepatide | — | 2026-07-01 |
| PRECLINICAL | evidence | Tirzepatide and Cardioprotection in Type 2 Diabetes: Insights From SURPASS-CVOT. | Tirzepatide | — | 2026-07-01 |
| PRECLINICAL | evidence | Tirzepatide-Induced Functional Small Bowel Obstruction in a Surgically Naive Patient: A Case Report. | Tirzepatide | — | 2026-07-01 |
| PRECLINICAL | evidence | Approved weight loss drugs for obesity with a thorough emphasis on GLP-1 agonist medications: A systematic review. | Tirzepatide | Weight & fat loss | 2026-07-01 |
| PRECLINICAL | evidence | GLP-1-based therapy and ICD-10-documented heart failure or respiratory failure events in non-diabetic adults with rheumatoid arthritis and obesity: a TriNetX federated cohort study. | Tirzepatide | — | 2026-07-01 |
| PRECLINICAL | evidence | Glucagon-Like Peptide-1 Receptor Agonists: Their Therapeutic Potential in Cystic Fibrosis. | Tirzepatide | Glycemic control | 2026-07-01 |
| PRECLINICAL | evidence | Effect of Incretin-Based and Nonpharmacologic Weight Loss on Body Composition : A Systematic Review. | Tirzepatide | Weight & fat loss | 2026-07-01 |
| PRECLINICAL | evidence | Combination of prolonged water fasting and GLP-1 for refractory morbid obesity: Case report. | Tirzepatide | Weight & fat loss | 2026-07-01 |
| PRECLINICAL | evidence | Drug-Associated Ketoacidosis: A Comprehensive Disproportionality Analysis Based on the FAERS Database. | Tirzepatide | Glycemic control | 2026-07-01 |
| PRECLINICAL | evidence | Off-label GLP-1 receptor agonist and tirzepatide use for weight loss: patient safety and regulatory oversight. | Tirzepatide | — | 2026-07-01 |
| PRECLINICAL | evidence | Dietary Strategies and Nutritional Management in Patients Receiving GLP-1 and Dual GIP/GLP-1 Receptor Agonists as Adjuncts to Lifestyle Interventions: A Systematic Review of Randomised Clinical Trials. | Tirzepatide | Glycemic control | 2026-07-01 |
| PRECLINICAL | evidence | Indirect Comparative Efficacy and Safety of Tirzepatide Versus Oral Semaglutide for the Treatment of Overweight and Obesity. | Tirzepatide | Weight & fat loss | 2026-07-01 |
| PRECLINICAL | evidence | A Case of Severe Hypercalcemia in a Patient Taking Tirzepatide: Potential Risk Factors. | Mounjaro | — | 2026-07-01 |
| PRECLINICAL | evidence | Clinical Characteristics of Users of Weight Loss Drugs: Population-Based Case-Control Study. | Tirzepatide | Weight & fat loss | 2026-07-01 |
| PRECLINICAL | evidence | GLP-1 Receptor Agonist Therapy and Cardiorenal Outcomes in Type 1 Diabetes: A Propensity-Matched Real-World Analysis. | Tirzepatide | Glycemic control | 2026-07-01 |
| PRECLINICAL | evidence | Pre-Pregnancy GLP-1 Receptor Agonist or Tirzepatide Use and Gestational Diabetes Risk: Evaluating Pharmacodynamic Carry-Over Versus Post-Discontinuation Metabolic Rebound in a Multinational Federated Cohort. | Tirzepatide | Glycemic control | 2026-07-01 |
| PRECLINICAL | evidence | Incretin-Based Anti-obesity Medications in Polycystic Ovary Syndrome: The Evidence Map. | Tirzepatide | Weight & fat loss | 2026-07-01 |
| PRECLINICAL | evidence | Effects of GLP-1 Receptor Agonists on Psoriasis: An "Agent-Specific" Systematic Review of the Literature. | Tirzepatide | — | 2026-07-01 |
| PRECLINICAL | evidence | Switching patterns of GLP-1 receptor agonists from 2018 to 2025 in the largest private healthcare network in Poland. | Tirzepatide | Glycemic control | 2026-07-01 |
| PRECLINICAL | evidence | Ocular complications associated with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) - Clinical evidence and insights. | Tirzepatide | Glycemic control | 2026-07-01 |
| PRECLINICAL | evidence | Glucagon-Like Peptide-1 Receptor Agonist and Hyponatremia: A Potential Association. | Tirzepatide | — | 2026-07-01 |
| PRECLINICAL | evidence | American Society for Metabolic and Bariatric Surgery statement on the treatment options for patients with non-response and weight recurrence after metabolic and bariatric surgery. | Tirzepatide | Weight & fat loss | 2026-07-01 |
| PRECLINICAL | evidence | Early cardiovascular-kidney-metabolic progression with tirzepatide: population definition and clinical interpretation. | Tirzepatide | — | 2026-07-01 |
| PRECLINICAL | evidence | Glucagon-like peptide-1 receptor agonists and hair loss: A systematic review and meta-analysis. | Tirzepatide | Glycemic control | 2026-07-01 |
| PRECLINICAL | evidence | Starvation-Type Euglycemic Ketoacidosis After Unsupervised Tirzepatide Use in a Non-Obese, Non-Diabetic Woman. | Tirzepatide | Glycemic control | 2026-07-01 |
| PRECLINICAL | evidence | Weight loss and cardiovascular outcomes with incretin-based therapies after metabolic and bariatric surgery: a nationwide US cohort study. | Tirzepatide | — | 2026-07-01 |
| PRECLINICAL | evidence | Association of Tirzepatide versus Glucagon-Like Peptide-1 Receptor Agonists with Incident Glaucoma in Patients with Type 2 Diabetes: A Retrospective Cohort Study. | Tirzepatide | — | 2026-07-01 |
| PRECLINICAL | evidence | Tirzepatide as a multi-organ integrator in metabolic diseases: a review of molecular mechanisms and clinical translation. | Tirzepatide | Glycemic control | 2026-07-01 |
| PRECLINICAL | evidence | Comparative Effectiveness of CagriSegma, Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta-Analysis of Randomized Clinical Trials. | Tirzepatide | Weight & fat loss | 2026-07-01 |
| PRECLINICAL | evidence | Tirzepatide Is Associated With Improved Metabolic Outcomes in People With Type 1 Diabetes and Overweight or Obesity: A Retrospective Cohort Study. | Tirzepatide | — | 2026-07-01 |
| PRECLINICAL | evidence | Cardiorenal outcomes of weight loss interventions in people with CKD and type 2 diabetes. | Tirzepatide | Weight & fat loss | 2026-06-30 |
| PRECLINICAL | evidence | Endotypic trait responses to 12-month tirzepatide treatment for an obese patient with obstructive sleep apnea: a case report. | Tirzepatide | — | 2026-06-30 |
| PRECLINICAL | evidence | Tirzepatide Versus Conventional Glucagon-Like Peptide-1 Receptor Agonists for Treatment Simplification in Type 2 Diabetes Mellitus: A Real-World Study. | Tirzepatide | — | 2026-06-30 |
| PRECLINICAL | evidence | Real-World Comparative Effectiveness of Tirzepatide and Semaglutide for Obesity: A Multicentered Study. | Tirzepatide | — | 2026-06-30 |
| PRECLINICAL | evidence | Evaluation of the Clinical Effectiveness and Cost-Effectiveness of Tirzepatide for Type 2 Diabetes in Canada Using Bayesian Transportability Analysis. | Tirzepatide | — | 2026-06-30 |
| PRECLINICAL | evidence | Neuropsychiatric association of tirzepatide and semaglutide in obesity with and without type 2 diabetes. | Tirzepatide | — | 2026-06-29 |